-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In recent years, under the background of accelerated changes in the pharmaceutical environment, many pharmaceutical companies have begun to adjust their development strategies, such as Roche, Eli Lilly, GSK, Takeda, Pfizer and other companies are actively starting to accelerate their weight loss and adjust their business
.
Recently, it was reported that Sanofi had transferred the rights of the antipsychotic drug Teralithe LP 400mg long-acting preparation and Teralithe 250mg divisible tablet in France to Laboratoires DELBERT.
The two parties signed an agreement on March 31 this year
.
It is reported that Teralithe LP 400mg and Teralithe 250mg are both oral antipsychotic drugs, which currently only account for a small part of Sanofi's pharmaceutical business sales
.
With this acquisition, Laboratoires DELBERT will strengthen its CNS portfolio
.
It is worth noting that splitting "slim down" has become an important means for Sanofi to increase revenue and reduce expenditure
.
As early as two years ago, Sanofi began to split the API business
.
In February 2020, Sanofi announced plans to combine six API manufacturing sites in Europe to create an API company that manufactures and sells active pharmaceutical ingredients to third parties
.
In January 2021, Sanofi officially named the new company focused on APIs EUROAPI, appointing Karl Rotthier, former CEO of Dutch drugmaker Centrient Pharmaceuticals, as CEO
.
On April 1, the multinational pharmaceutical company Daiichi Sankyo also announced that it will sign an equity transfer agreement with Chongqing Yaoyou Pharmaceutical, a subsidiary of Fosun Pharma, to transfer the production and sales rights of Colibidone tablets and Colibiduo injections in mainland China.
And the entire equity of Daiichi Sankyo Pharmaceutical (Beijing) Co.
, Ltd.
, which produces the preparation
.
Before this transfer, in fact, Daiichi Sankyo has also successively sold mature product businesses
.
For example, last year, Daiichi Sankyo transferred the production and sales rights of 11 mature drugs in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a holding subsidiary of Alfresa.
.
At that time, Daiichi Sankyo stated that in the future, while optimizing its business, it would focus more of its resources on the field of oncology
.
In addition to multinational pharmaceutical companies, in order to have a better development status, in order to have a better development status, many domestic pharmaceutical companies have It is also choosing to actively focus on the main business and accelerate the "slimming"
.
For example, on January 25, Hefei Lifang Pharmaceutical issued an announcement on the transfer of part of the equity of the participating company, agreeing to transfer the 4.
9383% equity of Minowei held to Pingtan Wenzhou Ruiji Investment Partnership at a price of 32.
0988 million yuan.
(Limited Partnership) Pingtan Fanrun Enterprise Management Partnership (Limited Partnership)
.
On January 19, Ruikang Pharmaceutical announced that the company planned to transfer 51% of Honglin Pharmaceuticals shares, and Wang Hongliang took over
.
According to the announcement, the legal representative of Honglin Pharmaceutical is Wang Hongliang, and the company's business scope includes Chinese patent medicine, Chinese herbal decoction pieces, and chemical pharmaceutical preparations
.
The company was previously held 51% by Ruikang Pharmaceuticals and 49% by Wang Hongliang, and is currently wholly-owned by Wang Hongliang.
.
.
On the whole, a large number of domestic and foreign pharmaceutical companies have divested related businesses, mainly due to two reasons, some of which are Due to the impact of performance, it had to sell and transfer "return to blood"
.
Another part of the enterprise is to gather resources and re-plan the development layout
.
But no matter what the reason is, this shows that the competition in the pharmaceutical industry is becoming more and more fierce.
The development model of pharmaceutical companies that only relied on individual blockbuster products to support revenue in the past is becoming more and more risky.
In the future, pharmaceutical companies will only continue to improve.
Product lines and expanding core areas can ensure better development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Recently, it was reported that Sanofi had transferred the rights of the antipsychotic drug Teralithe LP 400mg long-acting preparation and Teralithe 250mg divisible tablet in France to Laboratoires DELBERT.
The two parties signed an agreement on March 31 this year
.
It is reported that Teralithe LP 400mg and Teralithe 250mg are both oral antipsychotic drugs, which currently only account for a small part of Sanofi's pharmaceutical business sales
.
With this acquisition, Laboratoires DELBERT will strengthen its CNS portfolio
.
It is worth noting that splitting "slim down" has become an important means for Sanofi to increase revenue and reduce expenditure
.
As early as two years ago, Sanofi began to split the API business
.
In February 2020, Sanofi announced plans to combine six API manufacturing sites in Europe to create an API company that manufactures and sells active pharmaceutical ingredients to third parties
.
In January 2021, Sanofi officially named the new company focused on APIs EUROAPI, appointing Karl Rotthier, former CEO of Dutch drugmaker Centrient Pharmaceuticals, as CEO
.
On April 1, the multinational pharmaceutical company Daiichi Sankyo also announced that it will sign an equity transfer agreement with Chongqing Yaoyou Pharmaceutical, a subsidiary of Fosun Pharma, to transfer the production and sales rights of Colibidone tablets and Colibiduo injections in mainland China.
And the entire equity of Daiichi Sankyo Pharmaceutical (Beijing) Co.
, Ltd.
, which produces the preparation
.
Before this transfer, in fact, Daiichi Sankyo has also successively sold mature product businesses
.
For example, last year, Daiichi Sankyo transferred the production and sales rights of 11 mature drugs in Japan, including the antihypertensive drug Acecol and the antibacterial drug Banan, to Alfresa Pharmaceuticals, a holding subsidiary of Alfresa.
.
At that time, Daiichi Sankyo stated that in the future, while optimizing its business, it would focus more of its resources on the field of oncology
.
In addition to multinational pharmaceutical companies, in order to have a better development status, in order to have a better development status, many domestic pharmaceutical companies have It is also choosing to actively focus on the main business and accelerate the "slimming"
.
For example, on January 25, Hefei Lifang Pharmaceutical issued an announcement on the transfer of part of the equity of the participating company, agreeing to transfer the 4.
9383% equity of Minowei held to Pingtan Wenzhou Ruiji Investment Partnership at a price of 32.
0988 million yuan.
(Limited Partnership) Pingtan Fanrun Enterprise Management Partnership (Limited Partnership)
.
On January 19, Ruikang Pharmaceutical announced that the company planned to transfer 51% of Honglin Pharmaceuticals shares, and Wang Hongliang took over
.
According to the announcement, the legal representative of Honglin Pharmaceutical is Wang Hongliang, and the company's business scope includes Chinese patent medicine, Chinese herbal decoction pieces, and chemical pharmaceutical preparations
.
The company was previously held 51% by Ruikang Pharmaceuticals and 49% by Wang Hongliang, and is currently wholly-owned by Wang Hongliang.
.
.
On the whole, a large number of domestic and foreign pharmaceutical companies have divested related businesses, mainly due to two reasons, some of which are Due to the impact of performance, it had to sell and transfer "return to blood"
.
Another part of the enterprise is to gather resources and re-plan the development layout
.
But no matter what the reason is, this shows that the competition in the pharmaceutical industry is becoming more and more fierce.
The development model of pharmaceutical companies that only relied on individual blockbuster products to support revenue in the past is becoming more and more risky.
In the future, pharmaceutical companies will only continue to improve.
Product lines and expanding core areas can ensure better development
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
